Lenalidomide Exposed, 1,2,3 prior line of therapy, Lenalidomide Refractory, B-Cell Maturation Antigens (BCMA) Bispecific Antibody, Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Daratumumab+Pomalidomide+Dexamethasone (DPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd), Teclistamab+Daratumumab
### Instruction:
Identify the study with the following condition. 
### Input:
Lenalidomide Exposed, 1,2,3 prior line of therapy, Lenalidomide Refractory, B-Cell Maturation Antigens (BCMA) Bispecific Antibody, Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Daratumumab+Pomalidomide+Dexamethasone (DPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd), Teclistamab+Daratumumab 
### Output:
Popular Name is MajesTEC-3, Study ID is NCT05083169